BioInvent

289 articles about BioInvent

• BioInvent and Human Genome Sciences, Inc. Announce Collaboration to Co-develop and Commercialize Therapeutic Antibodies

  3/11/2010

• BioInvent Announces a Directed New Share Issue of SEK 150 Million

  1/14/2010

• First Patient Treated in BioInvent's Phase I Study of the Drug Candidate BI-505 to Treat Multiple Myeloma

  1/4/2010

• BioInvent and ThromboGenics NV Win "Licensing Deal of the Year" at the Scrip Awards 2009

  11/19/2009

• ThromboGenics Ltd. and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumors

  11/16/2009

• BioInvent Signs Licensing Agreement with Daiichi Sankyo Co Ltd. for the Discovery and Development of Therapeutic Antibodies

  11/13/2009

• BioInvent and ThromboGenics Ltd. Complete Patient Recruitment of Phase II DVT Prophylaxis Study with Anti-Factor VIII (TB-402)

  10/29/2009

• BioInvent Interim Report: 1 January – 30 September 2009

  10/15/2009

• BioInvent Updates On The Progress Of The Phase II Trial Of The Long Acting Anticoagulant TB-402

  9/23/2009

• BioInvent Announces Approval to start Phase I Trial for BI-505 in Multiple Myeloma

  8/11/2009

• BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study with TB-402

  7/6/2009

• BioInvent Reports Positive Phase I Results for BI-204, in Development for Prevention of Cardiovascular Conditions Associated with Atherosclerosis

  5/6/2009

• BioInvent Interim Report

  4/16/2009

• BioInvent Presents Positive Preclinical Data for BI-505 in Myeloma

  2/27/2009

• BioInvent And ThromboGenics Ltd. Start Phase II Trial of TB-402

  2/23/2009

• BioInvent Financial Statement: 1 January – 31 December 2008

  2/12/2009

• ThromboGenics Ltd. and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)

  1/26/2009

• Roche Signs Cancer Alliance with BioInvent and ThromboGenics Ltd. Worth Up to $775M

  6/18/2008

• BioInvent and ThromboGenics Ltd. Report Positive Phase I Results for Anti-PlGF Cancer Therapeutic TB-403

  6/3/2008

• BioInvent and Genentech, Inc. Initiate Phase I Clinical Trial for BI-204

  1/15/2008